Pharmaceutical development shifted focus to setmelanotide, a selective MC4R agonist, which received FDA approval in 2020 specifically for genetic obesity syndromes with POMC or leptin receptor deficiency
In December 2025, the Centers for Medicare and Medicaid Services announced the upcoming launch of the Medicare GLP-1 Bridge program
And yet, its still one of the most misunderstood.In this episode, Im joined by exercise scientist and researcher Derrick Van Every , author of the 2025 review Load-Induced Human Skeletal Muscle Hypertrophy: Mechanisms, Myths, and Misconceptions , to separate what actually drives muscle growth from what simply shows up alongside hard training.Together, we break down the human evidence, challenge long-standing myths, and clarify how lifters and coaches should actually approach hypertrophy-focused training.In this episode, we cover:MECHANICAL TENSION AS THE PRIMARY DRIVER OF HYPERTROPHYWHAT ROLE IF ANY DOES METABOLIC STRESS PLAY IN MUSCLE GROWTHDOES THE PUMP CONTRIBUTE TO MUSCLE GROWTH?DO ACUTE CHANGES IN HORMONES FROM TRAINING INFLUENCE HYPERTROPHY OUTCOMESHOW SHOULD WE APPROACH TRAINING TO MAXIMIZE MUSCLE HYPERTROPHY?If you want a clear, evidence-based understanding of how muscle is actually built and how to structure your training around the variables that matter most, this conversation will bring clarity.WHERE TO CONNECT WITH ME:Follow Brandon on IG: Info on Brandons Coaching Services: [email protected] Brandons Website: METABOLIC & PHYSIOLOGIC FLEXIBILITY: BUILDING A BODY THAT ADAPTS WITH DR
Tanning, weight loss, anti-aging - what do we really know about peptides
En esta artculo se habla de la opcin rpida (ciruga) y la medicamentosa que suele ser ms lenta en mostrar sus beneficios
Our online pharmacist is available Monday to Friday, 8am-4pm (AWST): Phone: 1800 418 429 SMS: +61 483 913 912 Email: [email protected]
